S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.78 (-2.85%)
AAPL   141.97 (-2.34%)
MSFT   283.35 (-3.68%)
FB   340.65 (-3.66%)
GOOGL   2,717.19 (-3.69%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.20 (-4.80%)
BABA   152.12 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.30 (-6.49%)
AMD   101.01 (-6.61%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.12 (-1.03%)
BA   218.41 (-2.57%)
AMC   36.74 (-6.51%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.78 (-2.85%)
AAPL   141.97 (-2.34%)
MSFT   283.35 (-3.68%)
FB   340.65 (-3.66%)
GOOGL   2,717.19 (-3.69%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.20 (-4.80%)
BABA   152.12 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.30 (-6.49%)
AMD   101.01 (-6.61%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.12 (-1.03%)
BA   218.41 (-2.57%)
AMC   36.74 (-6.51%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.78 (-2.85%)
AAPL   141.97 (-2.34%)
MSFT   283.35 (-3.68%)
FB   340.65 (-3.66%)
GOOGL   2,717.19 (-3.69%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.20 (-4.80%)
BABA   152.12 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.30 (-6.49%)
AMD   101.01 (-6.61%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.12 (-1.03%)
BA   218.41 (-2.57%)
AMC   36.74 (-6.51%)
S&P 500   4,352.63 (-2.04%)
DOW   34,299.99 (-1.63%)
QQQ   359.78 (-2.85%)
AAPL   141.97 (-2.34%)
MSFT   283.35 (-3.68%)
FB   340.65 (-3.66%)
GOOGL   2,717.19 (-3.69%)
TSLA   775.75 (-1.97%)
AMZN   3,316.98 (-2.61%)
NVDA   206.20 (-4.80%)
BABA   152.12 (+1.29%)
NIO   35.05 (-4.68%)
CGC   14.23 (-3.26%)
GE   105.72 (+0.35%)
MU   70.30 (-6.49%)
AMD   101.01 (-6.61%)
T   27.23 (-0.62%)
F   14.32 (+1.13%)
ACB   6.81 (+6.57%)
DIS   174.45 (-2.14%)
PFE   43.12 (-1.03%)
BA   218.41 (-2.57%)
AMC   36.74 (-6.51%)
OTCMKTS:HYPMY

Hypera Stock Forecast, Price & News

$6.01
-0.05 (-0.74 %)
(As of 09/27/2021 03:45 PM ET)
Add
Compare
Today's Range
$5.96
$6.01
50-Day Range
$6.00
$7.25
52-Week Range
$4.33
$7.76
Volume1,600 shs
Average Volume13,096 shs
Market Capitalization$3.80 billion
P/E Ratio15.01
Dividend Yield2.64%
Beta0.91
30 days | 90 days | 365 days | Advanced Chart
Receive HYPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.


Hypera logo

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HYPMY
CIK
N/A
Employees
8,918
Year Founded
N/A

Sales & Book Value

Annual Sales
$793.81 million
Cash Flow
$0.44 per share
Book Value
$2.83 per share

Profitability

Net Income
$251.25 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$3.80 billion
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.20 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Hypera (OTCMKTS:HYPMY) Frequently Asked Questions

What stocks does MarketBeat like better than Hypera?

Wall Street analysts have given Hypera a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hypera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hypera?

Hypera saw a decrease in short interest in August. As of August 31st, there was short interest totaling 2,800 shares, a decrease of 46.2% from the August 15th total of 5,200 shares. Based on an average daily trading volume, of 33,400 shares, the days-to-cover ratio is presently 0.1 days.
View Hypera's Short Interest
.

How has Hypera's stock been impacted by Coronavirus?

Hypera's stock was trading at $6.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HYPMY shares have decreased by 14.0% and is now trading at $6.0050.
View which stocks have been most impacted by COVID-19
.

Is Hypera a good dividend stock?

Hypera pays an annual dividend of $0.16 per share and currently has a dividend yield of 2.64%.
View Hypera's dividend history.

Who are Hypera's key executives?

Hypera's management team includes the following people:
  • Mr. Breno Toledo Pires de Oliveira, Chief Exec. Officer
  • Mr. Adalmario Ghovatto Satheler do Couto, Investor Relations Officer & CFO
  • Mr. Carlos Roberto Scorsi, Chief Operating officer (Age 59)
  • Juliana Aguinaga Damião Salem, Chief Legal & Compliance Officer
  • Mr. Luiz Eduardo Sales Clavis, Commercial & Marketing VP
  • Mr. Nelson José de Mello, Chief Corp. Relations Officer (Age 62)
  • Mr. Hélio Segouras, Head of Consumer Health
  • Mr. Claudio Bergamo dos Santos, Pres of Pharma & Director (Age 56)
  • Mr. Martim Prado Mattos, Sec. (Age 41)
  • Mr. Luiz Eduardo Violland, Chief Exec. Officer of the Pharmaceutical Division

What is Hypera's stock symbol?

Hypera trades on the OTCMKTS under the ticker symbol "HYPMY."

How do I buy shares of Hypera?

Shares of HYPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hypera's stock price today?

One share of HYPMY stock can currently be purchased for approximately $6.01.

How much money does Hypera make?

Hypera has a market capitalization of $3.80 billion and generates $793.81 million in revenue each year.

How many employees does Hypera have?

Hypera employs 8,918 workers across the globe.

What is Hypera's official website?

The official website for Hypera is www.hyperapharma.com.br.

Where are Hypera's headquarters?

How can I contact Hypera?

Hypera's mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The company can be reached via phone at 55-11-3627-4206 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.